Literature DB >> 33079613

Tocilizumab prescribing criteria for COVID-19 patients.

Ayman M Al-Qaaneh1,2, Fuad H Al-Ghamdi1.   

Abstract

Entities:  

Keywords:  COVID-19; SARS-CoV-2; Tocilizumab; cytokine storm; interleukin 6; monoclonal antibody

Mesh：

Substances：

Year:  2020        PMID： 33079613      PMCID： PMC8018477          DOI： 10.1080/21645515.2020.1822137

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN： 2164-5515            Impact factor:   3.452


× No keyword cloud information.
  7 in total

Review 1.  Anti-cytokine therapy in novel coronavirus disease (COVID-19) – the first administration of tocilizumab in Hungary at a department of infectology

Authors:  Botond Lakatos; László Gopcsa; Enikő Gondos; Alexandra Riczu; Zsuzsa Várnai; Éva Nagy; Eszter Molnár; Gabriella Bekő; Ilona Bobek; Péter Reményi; János Szlávik; János Sinkó; István Vályi-Nagy
Journal:  Orv Hetil       Date:  2020-06       Impact factor: 0.540

2.  Tocilizumab treatment in COVID-19: A single center experience.

Authors:  Pan Luo; Yi Liu; Lin Qiu; Xiulan Liu; Dong Liu; Juan Li
Journal:  J Med Virol       Date:  2020-04-15       Impact factor: 2.327

3.  Supportive Treatment with Tocilizumab for COVID-19: A Systematic Review.

Authors:  Saeed K Alzghari; Valerie S Acuña
Journal:  J Clin Virol       Date:  2020-04-21       Impact factor: 3.168

Review 4.  Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy.

Authors:  Paola Toniati; Simone Piva; Marco Cattalini; Emirena Garrafa; Francesca Regola; Francesco Castelli; Franco Franceschini; Paolo Airò; Chiara Bazzani; Eva-Andrea Beindorf; Marialma Berlendis; Michela Bezzi; Nicola Bossini; Maurizio Castellano; Sergio Cattaneo; Ilaria Cavazzana; Giovanni-Battista Contessi; Massimo Crippa; Andrea Delbarba; Elena De Peri; Angela Faletti; Matteo Filippini; Matteo Filippini; Micol Frassi; Mario Gaggiotti; Roberto Gorla; Michael Lanspa; Silvia Lorenzotti; Rosa Marino; Roberto Maroldi; Marco Metra; Alberto Matteelli; Denise Modina; Giovanni Moioli; Giovanni Montani; Maria-Lorenza Muiesan; Silvia Odolini; Elena Peli; Silvia Pesenti; Maria-Chiara Pezzoli; Ilenia Pirola; Alessandro Pozzi; Alessandro Proto; Francesco-Antonio Rasulo; Giulia Renisi; Chiara Ricci; Damiano Rizzoni; Giuseppe Romanelli; Mara Rossi; Massimo Salvetti; Francesco Scolari; Liana Signorini; Marco Taglietti; Gabriele Tomasoni; Lina-Rachele Tomasoni; Fabio Turla; Alberto Valsecchi; Davide Zani; Francesco Zuccalà; Fiammetta Zunica; Emanuele Focà; Laura Andreoli; Nicola Latronico
Journal:  Autoimmun Rev       Date:  2020-05-03       Impact factor: 9.754

Review 5.  The possible pathophysiology mechanism of cytokine storm in elderly adults with COVID-19 infection: the contribution of "inflame-aging".

Authors:  Gholam Hossein Meftahi; Zohreh Jangravi; Hedayat Sahraei; Zahra Bahari
Journal:  Inflamm Res       Date:  2020-06-11       Impact factor: 6.986

Review 6.  The cytokine storm and COVID-19.

Authors:  Biying Hu; Shaoying Huang; Lianghong Yin
Journal:  J Med Virol       Date:  2020-09-30       Impact factor: 20.693

Review 7.  The pathogenesis and treatment of the `Cytokine Storm' in COVID-19.

Authors:  Qing Ye; Bili Wang; Jianhua Mao
Journal:  J Infect       Date:  2020-04-10       Impact factor: 38.637
  7 in total
  2 in total

1.  Comparative Study of Cytokine Storm Treatment in Patients with COVID-19 Pneumonia Using Immunomodulators.

Authors:  Felicia Marc; Corina Maria Moldovan; Anica Hoza; Sorina Magheru; Gabriela Ciavoi; Dorina Maria Farcas; Liliana Sachelarie; Gabriela Calin; Laura Romila; Daniela Damir; Alexandru Gratian Naum
Journal:  J Clin Med       Date:  2022-05-23       Impact factor: 4.964

2.  Safety of Tocilizumab in COVID-19 Patients and Benefit of Single-Dose: The Largest Retrospective Observational Study.

Authors:  Ayman M Al-Qaaneh; Fuad H Al-Ghamdi; Sayed AbdulAzeez; J Francis Borgio
Journal:  Pharmaceutics       Date:  2022-03-11       Impact factor: 6.321
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.